Glyscend Therapeutics announces initiation of phase 1 clinical trial on the heels of preclinical data presented at EASD 2021 on the metabolic benefits of its oral polymer-based duodenal exclusion therapy
Glyscend Therapeutics has initiated a phase 1 clinical trial in Australia investigating an oral polymer therapy that improves glucose homeostasis with weight loss in nonclinical models. The therapy targets mechanisms underlying bariatric surgery and aims to replicate its benefits without the need for surgery.